

# Quanterix™

## Quanterix CEO Leads Webinar on How Digital Biomarkers are Empowering Drug Development

September 18, 2018

*Top researchers join the discussion on biomarker innovations for accelerating drug development*

*Brief Quanterix business update to be provided as well*

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 18, 2018-- [Quanterix Corporation \(NASDAQ:QTRX\)](#), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky, will lead a webinar on Wednesday, Sept. 19 at 11 a.m., EDT on the power of biomarkers to disrupt drug development. During the webinar, Mr. Hrusovsky will also provide a brief business update for Quanterix.

The webinar, [Disrupting Drug Development with Digital Biomarkers and the Power of Precision Health](#), will provide insights on how Quanterix technology is enabling advances in drug development that have the potential to disrupt drug development processes through the use of ultra sensitive digital biomarkers obtained through minimally invasive sampling techniques. The webinar will explore actual use cases across several different disease categories where Quanterix' digital biomarkers are being used to increase drug safety and efficacy. Hrusovsky, who is also Founder of the Powering Precision Health summit, will also solicit perspectives from two leading digital biomarker researchers in the fields of Neurology and Oncology on their latest advances in developing next generation biomarkers on disease progression and minimally invasive early disease detection.

"Ultra sensitive digital biomarkers are catalyzing the potential for diseases to be detected less invasively and earlier in the disease cascade when theoretically the disease is more treatable," said Hrusovsky. "When deployed in drug development, digital biomarkers have the potential to complement traditional clinical endpoints, providing researchers with enhanced mechanistic understanding and measurement of a drug's efficacy and toxicity at an individual patient level. These advances in digital biomarker measurement offer the potential for ushering in new treatment options and improving human health."

Hrusovsky will be joined by world-renowned researchers who will share how they have deployed biomarker technology in the areas of neurology and oncology research, including:

- Dr. Henrik Zetterberg, Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg
- Dr. Andrew Nixon, Associate Professor in Medicine, Member of the Duke Cancer Institute

Designed for a wide range of stakeholders in healthcare, the webinar will provide a vision for the potential of digital biomarkers and Quanterix technologies to improve drug development processes.

This webinar is open to the public and can be accessed by [registering here](#), or through the Webinars page within the Resources & News section of the Quanterix website at [www.quanterix.com](http://www.quanterix.com).

### About Quanterix

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit <https://www.quanterix.com>.

### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180918005701/en/>

Source: Quanterix Corporation

PAN Communications

Lindsay Poole, 617-502-4300  
[quanterix@pancomm.com](mailto:quanterix@pancomm.com)